Presentation is loading. Please wait.

Presentation is loading. Please wait.

Histologic Features of Intestinal Thrombotic Microangiopathy in Patients with High Risk TMA after HSCT  Javier El-Bietar, MD, Mikako Warren, MD, Christopher.

Published byLeoš Moravec Modified over 5 years ago

Similar presentations

Presentation on theme: "Histologic Features of Intestinal Thrombotic Microangiopathy in Patients with High Risk TMA after HSCT  Javier El-Bietar, MD, Mikako Warren, MD, Christopher."— Presentation transcript:

1 Histologic Features of Intestinal Thrombotic Microangiopathy in Patients with High Risk TMA after HSCT  Javier El-Bietar, MD, Mikako Warren, MD, Christopher E. Dandoy, MD, MSc, Kasiani C. Myers, MD, Adam Lane, PhD, Gregory Wallace, DO, Stella M. Davies, MBBS, PhD, Sonata Jodele, MD  Biology of Blood and Marrow Transplantation  Volume 21, Issue 2, (February 2015) DOI: /j.bbmt Copyright © Terms and Conditions

2 Figure Intestinal microangiopathy
Biology of Blood and Marrow Transplantation  , DOI: ( /j.bbmt ) Copyright © Terms and Conditions

Download ppt "Histologic Features of Intestinal Thrombotic Microangiopathy in Patients with High Risk TMA after HSCT  Javier El-Bietar, MD, Mikako Warren, MD, Christopher."

Similar presentations

Identification of CD137+ IFN-g- CD4+ Alloreactive T Cells Post Myeloablative Double Cord Blood Transplant: A Synergistic Role in the Graft Verus Graft.

Identification of CD137+ IFN-g- CD4+ Alloreactive T Cells Post Myeloablative Double Cord Blood Transplant: A Synergistic Role in the Graft Verus Graft.
Reduced Intensity Conditioning Allogeneic Stem Cell Transplantation for Adults with Relapsed and Refractory Mantle Cell Lymphoma: A Single Center Retrospective.

Reduced Intensity Conditioning Allogeneic Stem Cell Transplantation for Adults with Relapsed and Refractory Mantle Cell Lymphoma: A Single Center Retrospective.
Variable Eculizumab Clearance Requires Pharmacodynamic Monitoring to Optimize Therapy for Thrombotic Microangiopathy after Hematopoietic Stem Cell Transplantation 

Variable Eculizumab Clearance Requires Pharmacodynamic Monitoring to Optimize Therapy for Thrombotic Microangiopathy after Hematopoietic Stem Cell Transplantation 
Trend, Risk Factors and Outcome of Thrombotic Microangiopathy in Pediatric Hematopoietic Stem Cell Transplant Recipients: A Multi-Institutional Review 

Trend, Risk Factors and Outcome of Thrombotic Microangiopathy in Pediatric Hematopoietic Stem Cell Transplant Recipients: A Multi-Institutional Review 
Biology of Blood and Marrow Transplantation

Biology of Blood and Marrow Transplantation
Peripheral Blood Expansion of CD38 Bright CD8+ Effector Memory T-Cells Predicts Acute Graft Versus Host Disease with a Diagnostic Accuracy of 87%  Pooja.

Peripheral Blood Expansion of CD38 Bright CD8+ Effector Memory T-Cells Predicts Acute Graft Versus Host Disease with a Diagnostic Accuracy of 87%  Pooja.
Michael A. Pulsipher, Christina Peters, Ching-Hon Pui 

Michael A. Pulsipher, Christina Peters, Ching-Hon Pui 
How to Treat MDS without Stem Cell Transplantation

How to Treat MDS without Stem Cell Transplantation
Kristen M. Coleman, RN, BSN, Stella M

Kristen M. Coleman, RN, BSN, Stella M
Biology of Blood and Marrow Transplantation

Biology of Blood and Marrow Transplantation
Histologic Features of Intestinal Thrombotic Microangiopathy in Pediatric and Young Adult Patients after Hematopoietic Stem Cell Transplantation  Javier.

Histologic Features of Intestinal Thrombotic Microangiopathy in Pediatric and Young Adult Patients after Hematopoietic Stem Cell Transplantation  Javier.
Variable Eculizumab Clearance Requires Pharmacodynamic Monitoring to Optimize Therapy for Thrombotic Microangiopathy after Hematopoietic Stem Cell Transplantation 

Variable Eculizumab Clearance Requires Pharmacodynamic Monitoring to Optimize Therapy for Thrombotic Microangiopathy after Hematopoietic Stem Cell Transplantation 
Infusion of Ex Vivo Expanded Cord Blood Progenitor Cells Is Associated with Reduced Hospital Days and Utilization of Opiate Infusion and Total Parenteral.

Infusion of Ex Vivo Expanded Cord Blood Progenitor Cells Is Associated with Reduced Hospital Days and Utilization of Opiate Infusion and Total Parenteral.
Continuous Intravenous Immunoglobulin and Platelet Infusion in Allogeneic Stem Cell Transplant Patients with Allo-Immune Thrombocytopenia  Katerina Ancevski,

Continuous Intravenous Immunoglobulin and Platelet Infusion in Allogeneic Stem Cell Transplant Patients with Allo-Immune Thrombocytopenia  Katerina Ancevski,
Richard Gopez Ancheta, MD, Carol Burian, CCRP, William E

Richard Gopez Ancheta, MD, Carol Burian, CCRP, William E
Vitamin A Deficiency Is Associated with Increased Risk of Acute Graft Versus Host Disease in Children  Dana T. Lounder, MD, Sonata Jodele, MD, Pooja Khandelwal,

Vitamin A Deficiency Is Associated with Increased Risk of Acute Graft Versus Host Disease in Children  Dana T. Lounder, MD, Sonata Jodele, MD, Pooja Khandelwal,
Predictive Value of Pre-Transplant PET/CT Scan before Autologous Stem Cell Transplant in Mantle Cell Lymphoma  Brian Hess, MD, Kathryn Trinkaus, Ph.D.,

Predictive Value of Pre-Transplant PET/CT Scan before Autologous Stem Cell Transplant in Mantle Cell Lymphoma  Brian Hess, MD, Kathryn Trinkaus, Ph.D.,
Impact of Pre-Transplant Minimal Residual Disease in Patients with AML Undergoing Myeloablative Cord Blood Transplantation  Filippo Milano, MD, PhD, Brent.

Impact of Pre-Transplant Minimal Residual Disease in Patients with AML Undergoing Myeloablative Cord Blood Transplantation  Filippo Milano, MD, PhD, Brent.
Thrombotic microangiopathy after allogeneic stem cell transplantation in the era of reduced-intensity conditioning: The incidence is not reduced  Avichai.

Thrombotic microangiopathy after allogeneic stem cell transplantation in the era of reduced-intensity conditioning: The incidence is not reduced  Avichai.
Eculizumab Treatment Improves Survival in Patients with High-Risk Hematopoietic Stem Cell Transplant (HSCT)-Associated Thrombotic Microangiopathy (TMA) 

Eculizumab Treatment Improves Survival in Patients with High-Risk Hematopoietic Stem Cell Transplant (HSCT)-Associated Thrombotic Microangiopathy (TMA) 

Similar presentations

Ads by Google